UNLABELLED: Hyperprolactinemia is an elevation ofprolactin level above the norm in two separate samples. Its prevalence is 0.4%. Hyperprolactinemia could be a side effect oftreatment of schizophrenia with conventional and some of the second generation antipsychotics. AIM: To compare the prevalence of hyperprolactinemia and its clinical symptoms in three groups: (1) patients with schizophrenia treated with risperidone, (2) those treated with olanzapine and (3) the control group. METHOD: Participants in the study were 60 schizophrenic patients: 26 treated with risperidone, 34 with olanzapine and 38 healthy, non-medicated volunteers. In all subjects a fasting morning blood sample was obtained and analyzed for serum prolactin levels. RESULTS: Investigators did not establish any statistically significant difference in the prevalence of hyperprolactinemia diagnosed with laboratory tests in patients treated with different atypical neuroleptics. Hyperprolactinemia was established in 92.3% patients treated with risperidone and in 76.5% patients treated with olanzapine and in 2.6% subjects of the control group. Clinical symptoms of hyperprolactinemia were established only in a part of the subjects with hiperprolactinemia diagnosed with laboratory tests.
UNLABELLED: Hyperprolactinemia is an elevation ofprolactin level above the norm in two separate samples. Its prevalence is 0.4%. Hyperprolactinemia could be a side effect oftreatment of schizophrenia with conventional and some of the second generation antipsychotics. AIM: To compare the prevalence of hyperprolactinemia and its clinical symptoms in three groups: (1) patients with schizophrenia treated with risperidone, (2) those treated with olanzapine and (3) the control group. METHOD:Participants in the study were 60 schizophrenicpatients: 26 treated with risperidone, 34 with olanzapine and 38 healthy, non-medicated volunteers. In all subjects a fasting morning blood sample was obtained and analyzed for serum prolactin levels. RESULTS: Investigators did not establish any statistically significant difference in the prevalence of hyperprolactinemia diagnosed with laboratory tests in patients treated with different atypical neuroleptics. Hyperprolactinemia was established in 92.3% patients treated with risperidone and in 76.5% patients treated with olanzapine and in 2.6% subjects of the control group. Clinical symptoms of hyperprolactinemia were established only in a part of the subjects with hiperprolactinemia diagnosed with laboratory tests.